已经接受多内的中度至重度阿尔茨海默病患者接受孟坦丁治疗:一项随机对照试验
Pierre N Tariot1, Martin R Farlow, George T Grossberg
1Department of Psychiatry, University of Rochester Medical Center, Monroe Community Hospital, Rochester, NY 14620, USA. pierre_tariot@urmc.rochester.edu
JAMA
|January 22, 2004
概括
在已经服用多尼西尔的中度至重度阿尔茨海默病 (AD) 患者中,孟曼丁改善了认知和日常生活活动. 这种阿尔茨海默病治疗耐受性很好,比安慰剂更好的结果.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年病的医生 老年病的医生
背景情况:
- 孟曼丁是一种N-甲基-D-酸盐受体对抗剂.
- 以前的试验证实了孟坦丁在中度至重度阿尔茨海默病 (AD) 的单一治疗中有效.
- 没有先前的试验评估了记忆素与胆酶抑制剂联合使用.
研究的目的:
- 与安慰剂相比,评估孟坦丁的疗效和安全性.
- 评估已经在稳定治疗多内佩齐尔的中度至重度AD患者的孟坦丁的有效性.
主要方法:
- 一项为期24周的随机,双盲,安慰剂对照试验,涉及404名中度至重度AD患者.
- 患者的迷你精神状态检查得分在5到14之间,并且服用了稳定的多尼佩西尔剂量.
- 主要结局包括严重障碍电池 (SIB) 和AD合作研究-日常生活活动 (ADCS-ADL19) 评分的变化.
主要成果:
- 在SIB评分 (P<.001) 和ADCS-ADL19评分 (P=.03) 中,孟坦丁比安慰剂显著改善.
- 全球结果指标 (CIBIC-Plus) 也有利于孟坦丁 (P=.03).
- 与安慰剂 (12.4%) 相比,较少的患者因不良事件而停止服用孟坦丁 (7.4%).
结论:
- 孟坦丁组合疗法显著改善了多尼西尔治疗阿兹海默症患者的认知功能,日常生活活动和整体结果.
- 在这个患者群体中,孟坦丁耐受性很好.
- 这些发现支持孟坦因作为中度至重度阿尔茨海默病的有价值的治疗选择.
更多相关视频
相关概念视频
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.8K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.8K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
933
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
933
Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease l: Introduction
38
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
38


